Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Allorion Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both of these actions are located within 1 distinct art unit, which indicates the company's current patent prosecution efforts are handled within a single specialized division of the patent office.
The company's prosecution involves 2 distinct examiners, ensuring that each of the 2 pending office actions is reviewed by a different individual. This distribution of work provides multiple perspectives on the company's applications and prevents any single examiner from having a sole influence on the overall portfolio.
RAMACHANDRAN, UMAMAHESWARI is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because this examiner is responsible for 1 out of the 2 total pending actions, the workload is split among the assigned examiners for the company's active biotechnology and pharmaceutical filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.7% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18674627 | EGFR INHIBITORS AND METHODS OF USE THEREOF | RAMACHANDRAN, UMAMAHESWARI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18254573 | AMINOHETEROARYL KINASE INHIBITORS | PECKHAM, RICHARD GRANT | 33d |
| 18674627 | EGFR INHIBITORS AND METHODS OF USE THEREOF | RAMACHANDRAN, UMAMAHESWARI | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18674627 | EGFR INHIBITORS AND METHODS OF USE THEREOF | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103§112 | Non-Final OA | — | Pending | May 24, 2024 |
| 18254573 | AMINOHETEROARYL KINASE INHIBITORS | PECKHAM, RICHARD GRANT | 1627 | §103 | Final Rejection | 33d | Pending | May 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAllorion Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Umamaheswari Ramachandran has the most, with 1 of Allorion Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
